|
[1]RUNYON BA,AASLD.Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012[J].Hepatology,2013,57(4):1651-1653.
|
|
[2]PLANAS R,MONTOLIU S,BALLESTE B,et al.Natural history of patients hospitalized for management of cirrhotic ascites[J].Clin Gastroenterol Hepatol,2006,4(11):1385-1394.
|
|
[3]HONDA K,SEIKE M,MURAKAMI K.Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis[J].World J Hepatol,2015,7(22):2404-2410.
|
|
[4]KIM MS,ONG M,QU X.Optimal management for alcoholic liver disease:conventional medications,natural therapy or combination?[J].World J Gastroenterol,2016,22(1):8-23.
|
|
[5]BIECKER E.Diagnosis and therapy of ascites in liver cirrhosis[J].World J Gastroenterol,2011,17(10):1237-1248.
|
|
[6]SOLE,SOLC,GINS P.Management of uninfected and infected ascites in cirrhosis[J].Liver Int,2016,36(Suppl 1):109-115.
|
|
[7] LENZ K,BUDER R,KAPUN L,et al.Treatment and management of ascites and hepatorenal syndrome:an update[J].Therap Adv Gastroenterol,2015,8(2):83-100.
|
|
[8] European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis[J].J Hepatol,2010,53(3):397-417.
|
|
[9] PEREZ-AYUSO RM,ARROYO V,PLANAS R,et al.Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites.Relationship between the diuretic response and the activity of the renin-aldosterone system[J].Gastroenterology,1983,84(5 Pt 1):961-968.
|
|
[10] BERNARDI M,SERVADEI D,TREVISANI F,et al.Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone in patients with liver cirrhosis and ascites[J].Digestion,1985,31(4):189-193.
|
|
[11] ANGELI P,FASOLATO S,MAZZA E,et al.Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis:results of an open randomised clinical trial[J].Gut,2010,59(1):98-104.
|
|
[12] ANGELI P,WONG F,WATSON H,et al.Hyponatremia in cirrhosis:results of a patient population survey[J].Hepatology,2006,44(6):1535-1542.
|
|
[13]ALESSANDRIA C,ELIA C,MEZZABOTTA L,et al.Prevention of paracentesis-induced circulatory dysfunction in cirrhosis:standard vs half albumin doses.A prospective,randomized,unblinded pilot study[J].Dig Liver Dis,2011,43(11):881-886.
|
|
[14]MANDORFER M,BOTA S,SCHWABL P,et al.Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis[J].Gastroenterology,2014,146(7):1680-1690.
|
|
[15] LEITHEAD JA,RAJORIYA N,TEHAMI N,et al.Non-selective beta-blockers are associated with improved survival in patients with ascites listed for liver transplantation[J].Gut,2015,64(7):1111-1119.
|
|
[16] KRAG A,MADSEN BS.To block,or not to block in advanced cirrhosis and ascites:that is the question[J].Gut,2015,64(7):1015-1017.
|
|
[17]GUO TT,YANG Y,SONG Y,et al.Effects of midodrine in patients with ascites due to cirrhosis:systematic review and meta-analysis[J].J Dig Dis,2016,17(1):11-19.
|
|
[18]BARI K,MINANO C,SHEA M,et al.The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis[J].Clin Gastroenterol Hepatol,2012,10(10):1169-1175.
|
|
[19]BELLOT P,WELKER MW,SORIANO G,et al.Automated low flow pump system for the treatment of refractory ascites:a multicenter safety and efficacy study[J].J Hepatol,2013,58(5):922-927.
|
|
[20] THOMAS MN,SAUTER GH,GERBES AL,et al.Automated low flow pump system for the treatment of refractory ascites:a singlecenter experience[J].Langenbecks Arch Surg,2015,400(8):979-983.
|
|
[21]PONZIANI FR.Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications[J].World J Gastroenterol,2015,21(43):12322.
|
|
[22] ASSEM M,ELSABAAWY M,ABDELRASHED M,et al.Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites:a prospective randomized open-label comparative multicenter study[J].Hepatol Int,2016,10(2):377-385.
|
|
[23] Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,Chinese Medical Association;Severe Liver Diseases and Artificial Liver Group,Chinese Society of Hepatology,Chinese Medical Association.Guidelines for diagnosis and treatment liver failure[J].Chin J Clin Infect Dis,2012,5(6):321-327.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版)[J].中华临床感染病杂志,2012,5(6):321-327.
|
|
[24]SOLA E,GINES P.Renal and circulatory dysfunction in cirrhosis:current management and future perspectives[J].J Hepatol,2010,53(6):1135-1145.
|
|
[25] WONG F.Recent advances in our understanding of hepatorenal syndrome[J].Nat Rev Gastroenterol Hepatol,2012,9(7):382-391.
|
|
[26]SERSTE T,GUSTOT T,RAUTOU PE,et al.Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites[J].J Hepatol,2012,57(2):274-280.
|
|
[27] STOCKAND JD.Vasopressin regulation of renal sodium excretion[J].Kidney Int,2010,78(9):849-856.
|
|
[28] YAMAMURA Y,NAKAMURA S,ITOH S,et al.OPC-41061,a highly potent human vasopressin V2-receptor antagonist:pharmacological profile and aquaretic effect by single and multiple oral dosing in rats[J].J Pharmacol Exp Ther,1998,287(3):860-867.
|
|
[29]SAKAIDA I,KAWAZOE S,KAJIMURA K,et al.Tolvaptan for improvement of hepatic edema:a phase 3,multicenter,randomized,double-blind,placebo-controlled trial[J].Hepatol Res,2014,44(1):73-82.
|
|
[30] IMAMURA T,KINUGAWA K,MINATSUKI S,et al.Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels[J].Int Heart J,2014(14):131-137.
|
|
[31] SAKAIDA I,NAKAJIMA K,OKITA K,et al.Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis?A post hoc analysis of previous clinical trials in Japan[J].J Gastroenterol,2015,50(10):1047-1053.
|
|
[32] SHOAF SE,BRICMONT P,MALLIKAARJUN S.Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function[J].Kidney Int,2014,85(4):953-961.
|
|
[33]GOLDSMITH SR,BART BA,BURNETT J.Decongestive therapy and renal function in acute heart failure:time for a new approach?[J].Circ Heart Fail,2014,7(3):531-535.
|
|
[34] VADUGANATHAN M,GHEORGHIADE M,PANG PS,et al.Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment[J].J Cardiovasc Med(Hagerstown),2012,13(7):415-422.
|
|
[35]UDELSON JE,ORLANDI C,OUYANG J,et al.Acute hemodynamic effects of tolvaptan,a vasopressin V2 receptor blocker,in patients with symptomatic heart failure and systolic dysfunction:an international,multicenter,randomized,placebo-controlled trial[J].J Am Coll Cardiol,2008,52(19):1540-1545.
|
|
[36]CARDENAS A,GINES P,MAROTTA P,et al.Tolvaptan,an oral vasopressin antagonist,in the treatment of hyponatremia in cirrhosis[J].J Hepatol,2012,56(3):571-578.
|
|
[37]AHLUWALIA V,HEUMAN DM,FELDMAN G,et al.Correction of hyponatremia improves cognition,quality of life,and brain edema in cirrhosis[J].J Hepatol,2015,1(62):75-82.
|
|
[38] KOGISO T,TOKUSHIGE K,HASHIMOTO E,et al.Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis[J].Hepatol Res,2016,46(3):e194-e200.
|
|
[39]ZHANG X,WANG SZ,ZHENG JF,et al.Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients[J].World J Gastroenterol,2014,20(32):11400-11405.
|
|
[40]OHKI T,SATO K,YAMADA T,et al.Efficacy of tolvaptan in patients with refractory ascites in a clinical setting[J].World J Hepatol,2015,7(12):1685-1693.
|
|
[41] TORRES VE,CHAPMAN AB,DEVUYST O,et al.Tolvaptan in patients with autosomal dominant polycystic kidney disease[J].NEngl J Med,2012,367(25):2407-2418.
|
|
[42] WATKINS PB,LEWIS JH,KAPLOWITZ N,et al.Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease:analysis of clinical trials database[J].Drug Saf,2015,38(11):1103-1113.
|
|
[43] YAN L,XIE F,LU J,et al.The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites:a meta-analysis of randomized controlled trials[J].BMC Gastroenterol,2015,15:65.
|
|
[44]PERICLEOUS M,SARNOWSKI A,MOORE A,et al.The clinical management of abdominal ascites,spontaneous bacterial peritonitis and hepatorenal syndrome:a review of current guidelines and recommendations[J].Eur J Gastroenterol Hepatol,2016,28(3):e10-e18.
|
|
[45] WONG F,WATSON H,GERBES A,et al.Satavaptan for the management of ascites in cirrhosis:efficacy and safety across the spectrum of ascites severity[J].Gut,2012,61(1):108-116.
|
DownLoad: